Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) released its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.02, Yahoo Finance reports. Armata Pharmaceuticals had a negative net margin of 887.54% and a negative return on equity of 139.56%.

Armata Pharmaceuticals Price Performance

Armata Pharmaceuticals stock opened at $2.68 on Wednesday. Armata Pharmaceuticals has a 52-week low of $0.83 and a 52-week high of $5.26.

Institutional Trading of Armata Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in shares of Armata Pharmaceuticals by 5.6% in the 4th quarter. Renaissance Technologies LLC now owns 73,696 shares of the company’s stock worth $91,000 after acquiring an additional 3,900 shares during the period. Vanguard Group Inc. raised its holdings in shares of Armata Pharmaceuticals by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company’s stock worth $1,335,000 after purchasing an additional 10,400 shares in the last quarter. Northern Trust Corp bought a new stake in shares of Armata Pharmaceuticals in the 1st quarter worth approximately $95,000. Jane Street Group LLC bought a new stake in shares of Armata Pharmaceuticals in the 4th quarter worth approximately $25,000. Finally, HRT Financial LP bought a new stake in shares of Armata Pharmaceuticals in the 4th quarter worth approximately $52,000. 3.28% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Monday, August 14th.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.